Jeffrey Palmer

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

Joanne Jones, JANE ANDERSON, Chia‐Ling Phuah et al. · Brain · 2010 · 164 citations · Full text

Life Sciences, Immunology, Neurology +17

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Gilbert H. Daniels, Anton Vladić, Vesna Brinar et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 149 citations

Life Sciences, Endocrinology, Pharmacotherapy +14

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Alasdair Coles, Edward Fox, Anton Vladić et al. · The Lancet Neurology · 2011 · 138 citations

Life Sciences, Immunology, Neurology +12

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

Kathryn R. Wagner, Hoda Abdel‐Hamid, Jean K. Mah et al. · Neuromuscular Disorders · 2020 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, CONTROLLED DOSE COMPARISON OF THALIDOMIDE FOR TREATMENT OF ERYTHEMA NODOSUM LEPROSUM

Laarni G. Villahermosa, Tranquilino T. Fajardo, Rodolfo M. Abalos et al. · American Journal of Tropical Medicine and Hygiene · 2005 · 50 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +9